Cerebral Blood Flow, Cerebral Blood Flow Reactivity to Acetazolamide, and Cerebral Blood Volume in Patients with Leukoaraiosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We have used single photon emission computed tomography to study cerebral blood flow (CBF), CBF reactivity to acetazolamide, and cerebral blood volume (CBV) in 15 subjects presenting widespread leukoaraiosis, with the aim of answering the question if chronic ischaemia or hypo metabolism is associated with leukoaraiosis. We compared these subjects to 9 controls presenting no leukoaraiosis but with similarly distributed factors for leukoaraiosis. The subjects with leukoaraiosis showed a low regional (r)CBF in their white matter, while CBV and CBF reactivity to acetazolamide were not significantly affected. rCBF, rCBV and rCBF reactivity to acetazolamide did not differ between the cortex of patients and controls. Our results suggest that the low white matter CBF of the patients with leukoaraiosis was related mainly to hypometabolism and not to oligaemia. The capacity of the cerebral vessels to vasodilate does not appear to be affected by leukoaraiosis.

Related collections

Author and article information

Journal

Journal ID (publisher-id): CED

Journal ID (nlm-ta): Cerebrovasc Dis

Journal ID (doi): 10.1159/issn.1015-9770

Title: Cerebrovascular Diseases

Publisher: S. Karger AG

ISSN (Print): 1015-9770

ISSN (Electronic): 1421-9786

Publication date Subscription-year: 1994

Publication date (Print): 1994

Publication date (Electronic): 25 May 1994

Volume: 4

Issue: 4

Pages: 287-293

Affiliations

^a Department of Neurology, ^b INSERM U 230, and ^c Department of Neuroradiology, Hôpital Purpan, Toulouse, France

Article

Publisher ID: 108496 Other ID: Cerebrovasc Dis 1994;4:287–293

DOI: 10.1159/000108496

SO-VID: 64a539af-e121-480e-95b1-8a06f36be48b

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Sex and Gender in Neurodegenerative Diseases

Submit here before September 30, 2024

Cerebral Blood Flow, Cerebral Blood Flow Reactivity to Acetazolamide, and Cerebral Blood Volume in Patients with Leukoaraiosis

Read this article at

Abstract

Related collections

Karger: Neurology and Neuroscience

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 502